Efficacy of the progesterone receptor antagonist mifepristone for palliative therapy of patients with a variety of advanced cancer types

Anticancer Research

Volumn 30, Issue 2, 2010, Pages 623-628

  Check, Jerome H ^a   Dix, Ebony ^a   Cohen, Rachael ^a   Check, Diane ^a   Wilson, Carrie ^a  

^a UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

Author keywords

Metastatic human cancer; Mifepristone; Palliation; Progesterone receptor antagonist; Tumor microenvironment

Indexed keywords

CAPECITABINE; CARBOPLATIN; CISPLATIN; DOCETAXEL; ERLOTINIB; GEMCITABINE; LETROZOLE; MIFEPRISTONE; OCTREOTIDE; OXALIPLATIN; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER PALLIATIVE THERAPY; CLINICAL ARTICLE; COLON ADENOCARCINOMA; DRUG EFFICACY; DRUG TREATMENT FAILURE; FEMALE; HUMAN; KIDNEY PELVIS CARCINOMA; LEIOMYOSARCOMA; LIFE EXTENSION; MALE; MALIGNANT FIBROUS HISTIOCYTOMA; MULTIPLE CYCLE TREATMENT; OFF LABEL DRUG USE; PANCREAS CANCER; PANCREAS CARCINOMA; PRIORITY JOURNAL; THYMIC EPITHELIAL CELL CANCER; THYMIC EPITHELIAL CELL CARCINOMA; THYMUS CANCER; TRANSITIONAL CELL CARCINOMA; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; CARCINOMA, TRANSITIONAL CELL; COLONIC NEOPLASMS; FEMALE; HISTIOCYTOMA, MALIGNANT FIBROUS; HORMONE ANTAGONISTS; HUMANS; KIDNEY NEOPLASMS; LEIOMYOSARCOMA; MALE; MIDDLE AGED; MIFEPRISTONE; NEOPLASMS; PALLIATIVE CARE; PANCREATIC NEOPLASMS; RECEPTORS, PROGESTERONE; SURVIVAL RATE; THYMUS NEOPLASMS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77950532448     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Szekeres-Bartho J, Faust Z and Varga P: The expression of a progesterone-induced immunomodulatory protein in pregnancy lymphocytes. Am J Reprod Immunol 34: 342-348, 1995.
2. Check JH, Szekeres-Bartho J and O'Shaughnessy A: Progesterone induced blocking factor seen in pregnancy lymphocytes soon after implantation. Am J Reprod Immunol 35: 277-280, 1996.
3. Szekeres-Bartho J, Barakonyi A, Polgar B, Par G, Faust Z, Palkovics T and Szeresay L: The role of gamma/delta T-cells in progesterone-mediated immunomodulation during pregnancy: a review. Am J Reprod Immunol 42: 44-48, 1999.
4. Szekeres-Bartho J, Csernus V and Hadnagy J: The blocking effect of progesterone on lymphocyte responsiveness is receptor-mediated. Biol Immunol Reprod 15: 36, 1989.
5. Check JH, Nazari P, Goldberg J, Yuen W and Angotti D: A model for potential tumor immunotherapy based on knowledge of immune mechanisms responsible for spontaneous abortion. Med Hypoth 57: 337-343, 2001.
6. Acevedo HF, Tong JY and Hartsock RJ: Human chorionic gonadotropin-beta subunit gene expression in cultured human fetal and cancer cells of different types and origins. Cancer 76: 1467-1475, 1995.
7. Srivastava MD, Thomas A, Srivastava BIS and Check JH: Expression and modulation of progesterone-induced blocking factor (PIBF) and innate immune factors in human leukemia cell lines by progesterone and mifepristone. Leuk Lymph 48(8): 1610-1617, 2007.
8. Check JH, Sansoucie L, Chern J, Amadi N and Katz Y: Mifepristone treatment improves length and quality of survival of mice with spontaneous leukemia. Anticancer Res 29: 2977-2980, 2009.
9. Check JH, SanSoucie L, Chern J and Dix E: Mifepristone treatment improves length and quality of survival of mice with spontaneous lung cancer. Anticancer Res, in press.
10. Check JH, Dix E, SanSoucie L, Amadi C, Check D and Brando K: Treatment with mifepristone improves the length and quality of life in mice with a strong predisposition to spontaneous testicular cancer. Proceedings of the 99th Annual Meeting of the American Association for Cancer Research; 2008 April 12-16; San Diego, CA, abstract number 2154.
11. Dix E, Check JH, SanSoucie L, Check D and Amadi C: The effect of treatment with mifepristone on the length and quality of life of mice with a strong predisposition for prostate cancer. In: Proceedings of the 99th Annual Meeting of the American Association for Cancer Research, April 12-16, 2008, San Diego, California, 2008.
12. Check JH, Dix E, Sansoucie L and Check D: Mifepristone may halt progression of extensively metastatic human adenocarcinoma of the colon - case report. Anticancer Res 29: 1611-1614, 2009.
13. Baulieu EE: Contragestion and other clinical applications of RU 486, an antiprogesterone at the receptor. Science 245: 1351-1357, 1989.
14. Rauch M, Loosfelt H, Philibert D and Milgrom E: Mechanism of action of an antiprogresterone RU 486, in the rabbit endometrium: Effects of RU 486 on the progesterone receptor and on expression of the uteroglobin gene. Eur J Biochem 148: 213-218, 1985.
15. Grunberg SM, Weiss MH, Spitz IM, Ahmadi J, Sadun A, Russell CA, Lucci L and Stevenson LL: Treatment of unresectable meningiomas with the antiprogesterone agent mifepristone. J Neurosurg 74: 861-866, 1991.
16. Grunberg SM: Role of antiprogestational therapy for meningiomas. Hum Reprod 9: 202-207, 1994.
17. Romieu G, Maudelonde T, Ulmann A, Pujol H, Grenier J, Cavahe G, Khalaf S and Rochefort H: The antiprogestin RU 486 in advanced breast cancer: Preliminary clinical trial. Bull Cancer 74: 455-461, 1987.
18. Klijin JG, de Jong FH, Bakker GH, Lamberts SW, Rodenburg CJ and Alexieva-Figusch J: Antiprogestins, a new form of endocrine therapy for human breast cancer. Cancer Res 49: 2851-2856, 1989.
19. Perrault D, Eisenhauer EA, Pritchard KI, Panasci L, Norris B, Vandenberg T and Fisher B: Phase II study of the progesterone antagonist mifepristone in patients with untreated metastatic breast carcinoma: A National Cancer Institute of Canada clinical trials group study. J Clin Oncol 14: 2709-2712, 1996.
20. Robertson JFR, Willsher PC, Winterbottom L, Blamey RW and Thorpe S: Onaprstone, a progesterone receptor antagonist, as first-line therapy in primary breast cancer. Eur J Cancer 35: 214-218, 1999.